Johnson & Johnson to Pay $700 Million to Settle Baby Powder Probe

The agreement in principle addresses an investigation brought by more than 40 states into the marketing of its talcum-based baby powder. 


 
Verizon's stock rockets as earnings bring a big wireless surprise

Verizon saw its best performance in four years on one metric tracking consumer wireless account growth. 


 
P&G Earnings Show Some Consumers Are Getting Used to Higher Prices

The consumer-products giant said that sales volume increased for categories including hair care and family care in the latest quarter. 


 
3M's stock suffering biggest selloff in 5 years after 2024 profit warning

3M's stock tanked Tuesday, after the consumer, industrial and healthcare-products company provided a 2024 profit outlook that was well below forecasts, which overshadowed fourth-quarter results that topped expectations. 


 
GE's stock drops after downbeat outlook for last full quarter before breakup

The aerospace, power and renewable energy company's disappointing profit outlook for the current overshadowed a fourth-quarter earnings beat that was fueled by strength in the GE Vernova businesses. 


 
Netflix to Pay $5 Billion for 'WWE Raw' Rights in Live Events Push

The multiyear deal will give the streaming giant exclusive rights to the hit wrestling show in the U.S. as well as international distribution rights in several countries. 


 
Amazon Fined in France Over Alleged Employee Surveillance

France's privacy watchdog fined Amazon.com's local warehouse management business, saying the company had put in place an "excessively intrusive" system to keep track of staff performance. 


 
Microsoft Balances SEC Disclosure Rules After Email Hack

Ongoing investigation finds no signs yet of material impact, company says. 


 
Why It Makes Sense for New EV Drivers to Look Beyond Tesla

The brand is pursuing a different approach to making its vehicles more affordable-and it's at the expense of existing Tesla owners. 


 
Sanofi to Buy Rare-Disease Assets From Inhibrx

Sanofi plans to buy assets from U.S. biopharmaceutical company Inhibrx in a deal valued at up to $2.2 billion.


(END) Dow Jones Newswires

01-23-24 1115ET